Can remission in rheumatoid arthritis be assessed without laboratory tests or a formal joint count? Possible remission criteria based on a self-report RAPID3 score and careful joint examination in the ESPOIR cohort

Journal of Rheumatology

Volumn 40, Issue 4, 2013, Pages 386-393

  Castrejón, Isabel ^a   Dougados, Maxime ^b   Combe, Bernard ^c   Guillemin, Francis ^d   Fautrel, Bruno ^e   Pincus, Theodore ^a  

^a NYU HOSPITAL FOR JOINT DISEASES   (United States)

^b Institut Cochin   (France)

^c LAPEYRONIE HOSPITAL   (France)

^d CHU NANCY BRABOIS   (France)

^e PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Patient questionnaires; Patient reported outcomes; Physician global assessment; Remission; Remission criteria; Rheumatoid arthritis

Indexed keywords

ADULT; ARTHRALGIA; ARTICLE; CLINICAL ASSESSMENT TOOL; CLINICAL DISEASE ACTIVITY INDEX; COHORT ANALYSIS; CONTROLLED STUDY; DAS28; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISEASE ACTIVITY; FEMALE; FORMAL JOINT COUNT; HUMAN; JOINT EXAMINATION; JOINT SWELLING; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUESTIONNAIRE; REMISSION; RESEARCH DIAGNOSTIC CRITERIA; RHEUMATOID ARTHRITIS; ROUTINE ASSESSMENT OF PATIENT INDEX DATA; SCORING SYSTEM; SELF REPORT; SENSITIVITY AND SPECIFICITY; SIMPLIFIED DISEASE ACTIVITY INDEX;

ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; C-REACTIVE PROTEIN; DIAGNOSTIC SELF EVALUATION; DISABILITY EVALUATION; FEMALE; HUMANS; JOINTS; MALE; MIDDLE AGED; PHYSICAL EXAMINATION; QUESTIONNAIRES; REMISSION INDUCTION; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84875858874     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.121059     Document Type: Article

References (56)

1. Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum 2011;63:573-86.
2. Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis 2011;70:404-13.
3. Fransen J, Creemers MCW, van Riel PLCM. Remission in rheumatoid arthritis: Agreement of the Disease Activity Score (DAS28) with the ARA preliminary remission criteria. Rheumatology 2004;43:1252-5.
4. Aletaha D, Smolen JS. The Simplified Disease Activity Index and Clinical Disease Activity Index to monitor patients in standard clinical care. Rheum Dis Clin North Am 2009;35:759-72.
5. Pincus T, Segurado OG. Most visits of most patients with rheumatoid arthritis to most rheumatologists do not include a formal quantitative joint count. Ann Rheum Dis 2006;65:820-2.
6. Pincus T, Swearingen CJ, Bergman MJ, Colglazier CL, Kaell A, Kunath A, et al. RAPID3 on an MDHAQ is correlated significantly with activity levels of DAS28 and CDAI, but scored in 5 versus more than 90 seconds. Arthritis Care Res 2010;62:181-9.
7. Hart LE, Tugwell P, Buchanan WW, Norman GR, Grace EM, Southwell D. Grading of tenderness as a source of interrater error in the Ritchie articular index. J Rheumatol 1985;12:716-7.
8. Lewis PA, O'Sullivan MM, Rumfeld WR, Coles EC, Jessop JD. Significant changes in Ritchie scores. Br J Rheumatol 1988;27:32-6.
9. Klinkhoff AV, Bellamy N, Bombardier C, Carette S, Chalmers A, Esdaile JM, et al. An experiment in reducing interobserver variability of the examination for joint tenderness. J Rheumatol 1988;15:492-4.
10. Thompson PW, Hart LE, Goldsmith CH, Spector TD, Bell MJ, Ramsden MF. Comparison of four articular indices for use in clinical trials in rheumatoid arthritis: patient, order and observer variation. J Rheumatol 1991;18:661-5.
11. Scott DL, Choy EHS, Greeves A, Isenberg D, Kassinor D, Rankin E, et al. Standardising joint assessment in rheumatoid arthritis. Clin Rheumatol 1996;15:579-82.
12. Kvien TK, Mowinckel P, Heiberg T, Dammann KL, Dale O, Aanerud GJ, et al. Performance of health status measures with a pen based personal digital assistant. Ann Rheum Dis 2005; 64:1480-4.
13. Sokka T, Pincus T. Joint counts to assess rheumatoid arthritis for clinical research and usual clinical care: Advantages and limitations. Rheum Dis Clin North Am 2009;35:713-22.
14. Tugwell P, Wells G, Strand V, Maetzel A, Bombardier C, Crawford B, et al. Clinical improvement as reflected in measures of function and health-related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: Sensitivity and relative efficiency to detect a treatment effect in a twelve-month, placebo-controlled trial. Arthritis Rheum 2000;43:506-14.
15. Strand V, Scott DL, Emery P, Kalden JR, Smolen JS, Cannon GW, et al. Physical function and health related quality of life: Analysis of 2-year data from randomized controlled studies of leflunomide, sulfasalazine or methotrexate in patients with active rheumatoid arthritis. J Rheumatol 2005;32:590-601.
16. Pincus T, Amara I, Segurado OG, Bergman M, Koch GG. Relative efficiencies of physician/assessor global estimates and patient questionnaire measures are similar to or greater than joint counts to distinguish adalimumab from control treatments in rheumatoid arthritis clinical trials. J Rheumatol 2008;35:201-5.
17. Pincus T, Bergman MJ, Yazici Y, Hines P, Raghupathi K, Maclean R. An index of only patient-reported outcome measures, Routine Assessment of Patient Index Data 3 (RAPID3), in two abatacept clinical trials: Similar results to Disease Activity Score (DAS28) and other RAPID indices that include physician-reported measures. Rheumatology 2008;47:345-9.
18. Wells G, Li T, Maxwell L, Maclean R, Tugwell P. Responsiveness of patient reported outcomes including fatigue, sleep quality, activity limitation, and quality of life following treatment with abatacept for rheumatoid arthritis. Ann Rheum Dis 2008;67:260-5.
19. Pincus T, Hines P, Bergman MJ, Yazici Y, Rosenblatt LC, Maclean R. Proposed severity and response criteria for Routine Assessment of Patient Index Data (RAPID3): Results for categories of disease activity and response criteria in abatacept clinical trials. J Rheumatol 2011;38:2565-71.
20. Pincus T, Furer V, Keystone E, Yazici Y, Bergman MJ, Luijtens K. RAPID3 (Routine Assessment of Patient Index Data) severity categories and response criteria: Similar results to DAS28 and CDAI in the RAPID1 (Rheumatoid Arthritis Prevention of Structural Damage) clinical trial of certolizumab pegol (CZP). Arthritis Care Res 2011;63:1142-9.
21. Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum 1993;36:729-40.
22. Pincus T, Swearingen CJ, Bergman M, Yazici Y. RAPID3 (Routine Assessment of Patient Index Data 3), a rheumatoid arthritis index without formal joint counts for routine care: Proposed severity categories compared to DAS and CDAI categories. J Rheumatol 2008;35:2136-47.
23. Pincus T, Chung C, Segurado OG, Amara I, Koch GG. An index of patient self-reported outcomes (PRO Index) discriminates effectively between active and control treatment in 4 clinical trials of adalimumab in rheumatoid arthritis. J Rheumatol 2006; 33:2146-52.
24. Anderson J, Caplan L, Yazdany J, Robbins ML, Neogi T, Michaud K, et al. Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. Arthritis Care Res 2012;64:640-7.
25. Combe B, Benessiano J, Berenbaum F, Cantagrel A, Daures JP, Dougados M, et al. The ESPOIR cohort: A ten-year follow-up of early arthritis in France: methodology and baseline characteristics of the 813 included patients. Joint Bone Spine 2007;74:440-5.
26. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977;33:159-74.
27. Acock AC. A gentle introduction to Stata. 3rd ed. College Station, TX: Stata Press; 2010.
28. Coughlin SS, Trock B, Criqui MH, Pickle LW, Browner D, Tefft MC. Presentation: The logistic modeling of sensitivity, specificity, and predictive value of a diagnostic test. J Clin Epidemiol 1992;45:1-7.
29. Pincus T, Yazici Y, Sokka T. Complexities in assessment of rheumatoid arthritis: Absence of a single gold standard measure. Rheum Dis Clin North Am 2009;35:687-97.
30. Makinen H, Kautiainen H, Hannonen P, Sokka T. Is DAS28 an appropriate tool to assess remission in rheumatoid arthritis? Ann Rheum Dis 2005;64:1410-3.
31. Mikkelsen WM, Dodge H. A four year follow-up of suspected rheumatoid arthritis: The Tecumseh, Michigan, community health study. Arthritis Rheum 1969;12:87-91.
32. O'Sullivan JB, Cathcart ES. The prevalence of rheumatoid arthritis: Follow-up evaluation of the effect of criteria on rates in Sudbury, Massachusetts. Ann Intern Med 1972;76:573-7.
33. Tunn EJ, Bacon PA. Differentiating persistent from self-limiting symmetrical synovitis in an early arthritis clinic. Br J Rheumatol 1993;32:97-103.
34. Visser H, le Cessie S, Vos K, Breedveld FC, Hazes JMW. How to diagnose rheumatoid arthritis early: A prediction model for persistent (erosive) arthritis. Arthritis Rheum 2002;46:357-65.
35. Wolfe F, Hawley DJ. Remission in rheumatoid arthritis. J Rheumatol 1985;12:245-52.
36. Shahouri SH, Michaud K, Mikuls TR, Caplan L, Shaver TS, Anderson JD, et al. Remission of rheumatoid arthritis in clinical practice: Application of the American College of Rheumatology/European League Against Rheumatism 2011 remission criteria. Arthritis Rheum 2011;63:3204-15.
37. Aletaha D, Neogi T, Silman A, Funovits J, Felson DT, Bingham CO III, et al. 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010;62:2569-81.
38. Castrejón I, Pincus T. Differences in treat-to-target in patients with rheumatoid arthritis versus hypertension and diabetes: Consequences for clinical care. Bull NYU Hosp Jt Dis 2011;69:104-10.
39. Callahan LF, Bloch DA, Pincus T. Identification of work disability in rheumatoid arthritis: Physical, radiographic and laboratory variables do not add explanatory power to demographic and functional variables. J Clin Epidemiol 1992;45:127-38.
40. Wolfe F, Hawley DJ. The longterm outcomes of rheumatoid arthritis: Work disability: A prospective 18 year study of 823 patients. J Rheumatol 1998;25:2108-17.
41. Fex E, Larsson B, Nived K, Eberhardt K. Effect of rheumatoid arthritis on work status and social and leisure time activities in patients followed 8 years from onset. J Rheumatol 1998;25:44-50.
42. Sokka T, Kautiainen H, Möttönen T, Hannonen P. Work disability in rheumatoid arthritis 10 years after the diagnosis. J Rheumatol 1999;26:1681-5.
43. Barrett EM, Scott DG, Wiles NJ, Symmons DP. The impact of rheumatoid arthritis on employment status in the early years of disease: a UK community-based study. Rheumatology 2000;39:1403-9.
44. Lubeck DP, Spitz PW, Fries JF, Wolfe F, Mitchell DM, Roth SH. A multicenter study of annual health service utilization and costs in rheumatoid arthritis. Arthritis Rheum 1986;29:488-93.
45. Pincus T, Callahan LF, Sale WG, Brooks AL, Payne LE, Vaughn WK. Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. Arthritis Rheum 1984;27:864-72.
46. Wolfe F, Kleinheksel SM, Cathey MA, Hawley DJ, Spitz PW, Fries JF. The clinical value of the Stanford Health Assessment Questionnaire functional Disability Index in patients with rheumatoid arthritis. J Rheumatol 1988;15:1480-8.
47. Leigh JP, Fries JF. Mortality predictors among 263 patients with rheumatoid arthritis. J Rheumatol 1991;18:1307-12.
48. Maiden N, Capell HA, Madhok R, Hampson R, Thomson EA. Does social disadvantage contribute to the excess mortality in rheumatoid arthritis patients? Ann Rheum Dis 1999;58:525-9.
49. Sokka T, Hakkinen A, Krishnan E, Hannonen P. Similar prediction of mortality by the Health Assessment Questionnaire in patients with rheumatoid arthritis and the general population. Ann Rheum Dis 2004;63:494-7.
50. Sokka T, Abelson B, Pincus T. Mortality in rheumatoid arthritis: 2008 update. Clin Exp Rheumatol 2008;26 Suppl:S35-S61.
51. Pincus T, Askanase AD, Swearingen CJ. A Multi-Dimensional Health Assessment Questionnaire (MDHAQ) and Routine Assessment of Patient Index Data (RAPID3) scores are informative in patients with all rheumatic diseases. Rheum Dis Clin North Am 2009;35:819-27.
52. Yazici Y, Sokka T, Ricciardi DD, Pincus T. Differences in clinical status measures in different ethnic/racial groups with rheumatoid arthritis: implications for interpretation of clinical trial data. J Rheumatol 2007;34:311-5.
53. Aletaha D, Smolen J, Ward MM. Measuring function in rheumatoid arthritis: identifying reversible and irreversible components. Arthritis Rheum 2006;54:2784-92.
54. Pincus T, Wolfe F. An infrastructure of patient questionnaires at each rheumatology visit: improving efficiency and documenting care. J Rheumatol 2000;27:2727-30.
55. Pincus T, Oliver AM, Bergman MJ. How to collect an MDHAQ to provide rheumatology vital signs (function, pain, global status, and RAPID3 scores) in the infrastructure of rheumatology care, including some misconceptions regarding the MDHAQ. Rheum Dis Clin North Am 2009;35:799-812.
56. Pincus T, Skummer PT, Grisanti MT, Castrejón I, Yazici Y. MDHAQ/RAPID3 can provide a roadmap or agenda for all rheumatology visits when the entire MDHAQ is completed at all patient visits and reviewed by the doctor before the encounter. Bull NYU Hosp Jt Dis 2012;70:177-86.